Y90 + Atezolizumab and Bevacizumab for Liver Cancer

Northwestern University, Chicago, IL
Liver CancerAtezolizumab and Bevacizumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial aims to compare the effectiveness of two cancer treatments in adult patients with advanced liver cancer after Therasphere® treatment.

Eligible Conditions
  • Liver Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Similar Trials

Study Objectives

1 Primary · 6 Secondary · Reporting Duration: Up to 2 years

Up to 2 years
Adverse Events
Clinical Benefit Rates (CBR)
Duration of Response (DOR)
Objective Response Rate (ORR)
Overall Survival (OS)
Progression Free Survival (PFS)
Time to Progression (TTP)

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Y90 + Atezolizumab and Bevacizumab
1 of 2
Y90 + TKI
1 of 2

Experimental Treatment

84 Total Participants · 2 Treatment Groups

Primary Treatment: Y90 + Atezolizumab and Bevacizumab · No Placebo Group · Phase 2

Y90 + Atezolizumab and Bevacizumab
Experimental Group · 1 Intervention: Atezolizumab and Bevacizumab · Intervention Types: Drug
Y90 + TKI
Experimental Group · 1 Intervention: Y90 + TKI · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,502 Previous Clinical Trials
866,509 Total Patients Enrolled
8 Trials studying Liver Cancer
2,851 Patients Enrolled for Liver Cancer
National Cancer Institute (NCI)NIH
13,272 Previous Clinical Trials
41,230,644 Total Patients Enrolled
103 Trials studying Liver Cancer
21,168 Patients Enrolled for Liver Cancer
Aparna Kalyan, MDPrincipal InvestigatorNorthwestern University

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What implications does the combination of Y90, Atezolizumab and Bevacizumab have for patient health?

"Our team at Power gave Y90 + Atezolizumab and Bevacizumab a score of 2 in terms of safety, as the trial is only on Phase 2. This means that there is some data to support these treatments' security but none documenting their efficacy yet." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies for individuals to participate in this test?

"According to the clinicaltrials.gov page, this medical study is not currently accepting participants; it was first posted on November 25th 2022 and last updated on November 11th 2022. Nonetheless, there are 2,608 alternative trials actively recruiting patients at this time." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.